This trial will study a type of breast cancer defined by the expression of hormone receptor in the cancer cells (HR+). Patients will be treated with ribociclib, a cyclin-dependent kinase inhibitor, and camizestrant, a selective estrogen receptor degrader (SERD) and complete ER antagonist. The main purpose of the Study is to analyze the efficacy (to find out how effective a treatment is) of ribociclib in combination with camizestrant in patients with advanced HR+ breast cancer who have received endocrine therapy (ET) in early breast cancer setting for at least 5 years, of which at least 2 years with aromatase inhibitor (AI). Ribociclib plus camizestrant efficacy will be determined by assessing the period from treatment initiation until disease progression, defined as progression free survival (PFS).
The anticipated favorable clinical benefits of the combination of ribociclib and camizestrant therapy are projected to outweigh the risks of this treatment. This Study will be performed in full compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.

Start Date01 Dec 2025

Sponsor / Collaborator

Medica Scientia Innovation Research SL

NCT07085767

/ Not yet recruitingPhase 3

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Start Date31 Oct 2025

Sponsor / Collaborator

Olema Pharmaceuticals, Inc.

[+1]

NCT07174336

/ Not yet recruitingPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

The purpose of the study is to assess the efficacy and safety of the addition of LY4064809 to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.

Start Date01 Oct 2025

Sponsor / Collaborator

Eli Lilly & Co.

[+1]

100 Clinical Results associated with Ribociclib Succinate

100 Translational Medicine associated with Ribociclib Succinate

100 Patents (Medical) associated with Ribociclib Succinate

1,291

Literatures (Medical) associated with Ribociclib Succinate

01 Jan 2026·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Multi-omics integrative analysis elucidates the molecular characteristics of SMARCA4-deficient lung adenocarcinoma and the derived therapeutic options

Article

Author: Dong, Wei ; Chi, Yuxiang ; Wang, Kai ; Du, Jiajun ; Guo, Deyu ; Sun, Shijie

SMARCA4-deficient lung adenocarcinoma (LUAD) is highly aggressive with multiple oncogene mutations, and has low sensitivity to chemotherapy, targeted therapy and immunotherapy. By integrating multi-omics analysis and machine learning analysis on 20 lung adenocarcinoma datasets, we characterized SMARCA4 mutation in clinical prognosis, metabolic level, immune infiltration and pathway enrichment. The key role of SMARCA4 in LUAD development was confirmed by several in vitro and in vivo experiments. SMARCA4 is highly expressed in LUAD tissues compared with adjacent tissues, and SMARCA4 mutation is a poor prognostic factor. Although SMARCA4-deficient LUAD patients are not sensitive to common chemotherapeutic drugs, immunotherapy is an alternative treatment for lung adenocarcinoma. SMARCA4 deletion is associated with a high rate of oncogene co-mutation. Co-mutation of KRAS was found to have a significant impact on the response to multiple types of chemotherapy. Unique metabolic profiles, abnormal cell cycle and hyperactivation of oxidative phosphorylation were hallmarks of SMARCA4 mutant LUAD. We screened four chemotherapeutic agents targeting MTOR pathway, oxidative stress, DNA replication or cell cycle, including rapamycin and ribociclib, as potential chemotherapeutic agents for SMARCA4-deficient lung adenocarcinoma. In vitro assays showed that SMARCA4 knockdown significantly inhibited DNA replication, cell cycle and cell proliferation in lung adenocarcinoma cells, and significantly promoted oxidative stress and apoptosis in lung adenocarcinoma cells. Our comprehensive findings advance our understanding of SMARCA4 mutant LUAD gene mutation and immune microenvironment, providing insights into potential therapeutic approaches and research directions for SMARCA4-deficient LUAD.

01 Dec 2025·Eating Behaviors

Medications as precipitating factors for potential eating disorders: A disproportionality analysis using FDA adverse event reports

Article

Author: Zhang, Shuang ; Zheng, Liyun

OBJECTIVE:

Compared to psychosocial factors, medications remain less well recognized as precipitating factors for eating disorders. This study aims to identify medications potentially associated with eating disorders using the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) database.

METHODS:

FAERS reports related to potential eating disorders from January 2004 to December 2024 were retrieved. Reporting odds ratios (RORs) were calculated to detect disproportionate signals, with Fisher's exact test and Bonferroni correction applied for adjustments in multiple comparisons. Drugs exhibiting significant positive signals (ROR 95 % confidence interval lower bound >1, adjusted p-value < 0.01) with over 100 reports were selected for LASSO regression analysis. Logistic regression, adjusted for age, sex, and reporter type, was employed to identify precipitating drugs.

RESULTS:

Among 20,145 reports, 62.7 % involved females, with a median age of 59 years (interquartile range: 42-71). Thirty drugs showed significant positive signals. Nine potential precipitating medications were identified through LASSO and logistic regression, including octreotide, ribociclib, sunitinib, rivastigmine, everolimus, quetiapine, palbociclib, esomeprazole, and pregabalin.

CONCLUSION:

This study identifies certain medications that may act as precipitating factors for potential eating disorders, particularly in middle-aged and older populations. Clinicians should monitor these medications that affect appetite, weight, or carry abuse potential to prevent harm, especially in patients with eating disorders or at-risk populations.

01 Dec 2025·Biochemistry and Biophysics Reports

Identification and external validation of a prognostic signature based on myeloid-derived suppressor cells-related LncRNAs to evaluate survival prognosis and treatment efficacy in invasive breast carcinoma

Article

Author: Zhang, Wenxiong ; Xiang, Yuan ; Zhong, Yun ; Wang, Kang ; Zhang, Shunyao ; Mu, Tong ; Xie, Lei

Background:

Originating in the hematopoietic tissue, myeloid-derived suppressor cells (MDSCs) significantly contribute to tumor-related immunological processes. However, their relationship with long noncoding RNAs (lncRNAs) and breast cancer remains incompletely understood. In this study, we introduced MDSCs-associated lncRNAs as novel prognostic biomarkers to assess outcomes in patients with invasive breast carcinoma (BRCA).

Methods:

Information regarding BRCA cases, including clinical and genomic details, was obtained from the TCGA repository. Predictive indicators were discovered, and their reliability underwent thorough verification. A clinically useful nomogram was developed following application-based validation. Additional investigations encompassed functional analysis, TMB assessment, TME profiling, immunotherapy efficacy forecasting, and drug sensitivity testing along with target identification. Long non-coding RNA expression was measured using reverse transcription quantitative PCR.

Results:

A risk stratification model incorporating eight MDSCs-related lncRNAs effectively predicted patient outcomes. Kaplan-Meier (K-M) survival analysis clearly indicated a much worse prognosis among patients classified as high-risk (p < 0.001). The nomogram accurately forecasted overall survival (OS). Analysis of functional enrichment revealed that pathways associated with epithelial cells showed activity among patients at higher risk. Characterization of the tumor microenvironment showed increased immune cell presence in those classified as low-risk. Conversely, individuals with greater risk displayed higher tumor mutational burden. TIDE and IPS analyses indicated superior immunotherapy responsiveness in the low-risk BRCA subgroup. Among 47 drugs with notable IC50 variations, Ribociclib, PD173074, KU-55933, NU7441, and nutlin-3a exhibited lower IC50 values within the low-risk group, whereas Lapatinib demonstrated greater efficacy among the high-risk group. Moreover, 10 potential therapeutic agents and their targets were predicted for high-risk patients. RT-qPCR validation confirmed the robustness of the model.

Conclusions:

We successfully verified a new model of molecular markers of MDSCs-related lncRNAs, offering critical insights for predicting outcomes and guiding therapeutic decisions in BRCA cases.

386

News (Medical) associated with Ribociclib Succinate

21 Oct 2025

·endpoints.news

Elevara raises $70M to test a breast cancer approach in rheumatoid arthritis

A London-based biotech has secured $70 million to study its CDK4/6 inhibitor — a mechanism primarily used to treat breast cancer — in rheumatoid arthritis. Elevara Medicines emerged from stealth on Tuesday with the Series A raise and a drug candidate it in-licensed from Japan’s Teijin Pharma. The funds will be used to put the candidate, called ELV001, in a mid-stage trial in RA patients who have an inadequate response to methotrexate and TNF inhibitors, two standards of care. “RA hasn’t had a load of drug development over the last 10 years,” CEO Emma Tinsley told Endpoints News, adding that the Phase 1b data for ELV001 were “super exciting.” “They dosed 32 patients for seven days, and saw efficacy signals even within seven days, which for RA is very unusual,” she said. “We hope to replicate that as we move into the Phase 2 study.” In the Phase 2 trial, ELV001 will be dosed in combination with methotrexate and a TNF inhibitor. Elevara wants to enroll 180 patients, and expects to start recruiting by the end of the year. The candidate works by targeting fibroblast-like synoviocytes, cells that are a key driver of inflammation and joint damage in RA patients. While currently approved CDK4/6 inhibitors like Pfizer’s Ibrance, Eli Lilly’s Verzenio and Novartis’ Kisqali are approved to treat breast cancer patients, Tinsley said the mechanism holds potential in inflammatory conditions like RA because of its potential to target the proliferation of fibroblast-like synoviocytes, while at the same time reducing key inflammatory pathways. The Series A will also be used to support exploratory programs in other chronic inflammatory conditions and women’s health, Elevara said. The financing round was co-led by Forbion and Sofinnova Partners, with participation from Elevara’s founding investor Monograph Capital.

Phase 1Drug ApprovalPhase 2

21 Oct 2025

·www.globenewswire.com

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumors Combination continues to demonstrate favorable tolerability and a safety profile consistent with the known profiles of each drug Data support the ongoing Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline advanced or metastatic breast cancer Oct. 18, 2025 -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced updated data from the Phase 1b/2 study of palazestrant in combination with ribociclib in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. These findings will be presented in a poster session on October 20 at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. “We are very pleased with these latest data showing compelling progression-free survival and favorable tolerability of palazestrant plus ribociclib, further reinforcing this regimen’s potential as a new standard of care in metastatic breast cancer,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “These data showcase the activity of the combination in both ESR1 mutant and wild-type tumors, an important component for effective frontline treatment, and underscore the importance of complete ER antagonism in the treatment of ER-positive breast cancer. As we work to transform the breast cancer treatment paradigm, we are increasingly confident in palazestrant’s potential to become a best-in-class, backbone endocrine therapy and are excited to now have our second Phase 3 trial, OPERA-02, underway evaluating palazestrant with ribociclib in the frontline setting.” As of July 8, 2025, 72 patients were enrolled across the 90 mg and 120 mg palazestrant dose cohorts. 56 patients received 120 mg once-daily palazestrant and 16 patients received 90 mg once-daily palazestrant, all with the approved dose of ribociclib for metastatic breast cancer of 600 mg daily. 45 (63%) patients had prior treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy for advanced disease. 33% (15/45) of patients who had prior treatment with CDK4/6i in the advanced setting (2/3L) had an ESR1 mutation at baseline. In the 90 mg palazestrant dose cohort, with a median follow-up of 10.8 months, median progression-free survival (PFS) was not reached. In the 120 mg palazestrant dose cohort, with a median follow-up of more than 19 months, median PFS are mature. Median PFS was 15.5 months for all patients. Median PFS was 12.2 months for those who received prior treatment with CDK4/6i, including 9.2 months for patients with ESR1 wild-type tumors and 13.8 months for patients with tumors with ESR1 mutations. Across 72 patients treated, 90 mg or 120 mg of palazestrant combined with 600 mg of ribociclib daily was well tolerated with no new safety signals or increase in toxicity. Palazestrant and ribociclib did not demonstrate any drug-drug interactions and the overall safety profile was consistent with the established safety profile of ribociclib plus an endocrine therapy. The majority of treatment-emergent adverse events were grade 1 or 2, and the severity and incidence of adverse events were consistent with the expected safety profile of each drug. “Despite recent advances in the treatment of ER+/HER2- metastatic breast cancer, there remains a significant need for therapies that can overcome endocrine resistance, particularly following treatment with a CDK4/6 inhibitor,” said Dr. Nancy Lin, Associate Chief of the Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, at the Dana-Farber Cancer Institute. “I am very encouraged by these new data showing the novel palazestrant-ribociclib combination compares favorably to other endocrine therapy-CDK4/6 inhibitor combinations. With a compelling median PFS in the challenging post-CDK4/6 inhibitor setting, I believe palazestrant has the potential to serve as an important combination agent in the metastatic setting.” Title: Palazestrant (OP-1250) plus ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced breast cancer (ABC) Poster Number: 502P Session: Breast Cancer, Metastatic Session Date/Time: Monday, October 20, 2025, from 12:00-12:45pm CEST / 6:00-6:45am ET Additional information can be found on the ESMO 2025 website, including abstracts. A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the ESMO 2025 embargo policy. Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01 and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultFast Track

20 Oct 2025

·www.pharmaceutical-technology.com

ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer

Eli Lilly’s CDK 4/6 inhibitor, Verzenio, has been shown to prolong OS when used alongside endocrine therapy as an adjuvant treatment for HR+, HER2- early, high-risk breast cancer in a Phase III trial. Image credit: praetorianphoto, E+ via Getty Images. Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase III monarchE study, (NCT02763566), Verzenio plus endocrine therapy (ET) significantly reduced a patient’s risk of death compared with ET alone – slashing rates by 15.8%. Meanwhile, 86.8% of those given the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor plus ET were alive at the seven-year mark. This was compared to the 85% rate seen in the ET-only arm. Patients treated with Verzenio also experienced sustained improvements in both invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with 32% less patients living with metastatic disease compared with the ET monotherapy arm after a median follow-up of 6.3 years. However, it is yet to be determined if this will translate into a further OS benefit. The positive impact of Verzenio and ET as an adjuvant combination was seen in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative high-risk breast cancer . According to Lilly, these results mark Verzenio’s status as the first contemporary therapy to show benefit in this patient population for more than 20 years. They were first presented at a late-breaking oral presentation at the ongoing 2025 European Society of Medical Oncology (ESMO) congress, which is being held from 17–21 October in Berlin, Germany. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence These findings follow positive topline results from the Phase III monarchE trial shared in August 2025, which saw Verzenio-ET reduce a patient’s risk of recurrence by 34%. Following the outcome of this late-stage trial, Eli Lilly will share these data with global regulatory authorities. Verzenio in the breast cancer treatment paradigm While Eli Lilly’s Verzenio first won US Food and Drug Administration (FDA) approval in certain advanced or metastatic breast cancer indications back in 2017, the drug has since seen numerous label extensions. Now, its use has been expanded for use in patients with node-positive and high-risk early disease, as well as for use as a initial treatment. Through this enhanced market penetration, Verzenio has become a blockbuster seller for Lilly, raking in $5.3bn for the Indiana-based pharma in 2024. Moving forward, analysts at GlobalData forecast that the drug’s sales will continue to flourish, reaching a peak of $8.1bn in 2030. GlobalData is the parent company of Pharmaceutical Technology . However, it will still have to fight for market share with Novartis’ hard-hitter Kisqali (ribociclib), which was given the FDA nod alongside an aromatase inhibitor in the HR+, HER2- early breast cancer setting in 2024. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Clinical ResultPhase 3Drug Approval

100 Deals associated with Ribociclib Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Ribociclib Succinate	L01XE	DB11730

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced breast cancer	Canada	Novartis Pharmaceuticals Canada, Inc.	02 Mar 2018
Metastatic breast cancer	Canada	Novartis Pharmaceuticals Canada, Inc.	02 Mar 2018
Hormone receptor positive HER2 negative breast cancer	United States	Novartis Pharmaceuticals Corp.	13 Mar 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced HER2-Positive Breast Carcinoma	Phase 3	United States	Novartis AG	28 Mar 2022
Advanced HER2-Positive Breast Carcinoma	Phase 3	Portugal	Novartis AG	28 Mar 2022
Advanced HER2-Positive Breast Carcinoma	Phase 3	Spain	Novartis AG	28 Mar 2022
Early Stage Breast Carcinoma	Phase 3	-	Novartis Pharmaceuticals Corp.	31 Mar 2018
HER2-negative breast cancer	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Leukodystrophy, Hypomyelinating, 6	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Locally advanced breast cancer	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Breast Cancer	Phase 3	United States	Novartis Pharmaceuticals Corp.	07 Jun 2017
Advanced cancer	Phase 3	United States	Novartis Pharmaceuticals Corp.	30 Nov 2016
Advanced cancer	Phase 3	Argentina	Novartis Pharmaceuticals Corp.	30 Nov 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03822468 (AMALEE, Pubmed \| JAMA Oncol)	Phase 2	Advanced breast cancer First line HR+/ERBB2-	376	Ribociclib 600 mg + a nonsteroidal aromatase inhibitor (premenopausal patients also received goserelin)	zyhnfusiio(opjstyqlov): ratio = 0.87 (90.0% CI, 0.74 - 1.03)	Negative	25 Sep 2025
				Ribociclib 400 mg + a nonsteroidal aromatase inhibitor (premenopausal patients also received goserelin)
NCT03701334 (NATALEE, Pubmed \| JAMA Oncol)	Phase 3	Hormone receptor positive HER2 negative breast cancer Adjuvant hormone receptor-positive \| ERBB2 (formerly HER2)-negative	5,101	Ribociclib plus NSAI	zaabgbxffh(uuktorznfp) = xapwooqjad kpvqogrpcq (vwhqrlbhin ) View more	Positive	25 Sep 2025
				NSAI alone	zaabgbxffh(uuktorznfp) = uebcpyjndp kpvqogrpcq (vwhqrlbhin ) View more
NCT03913234 (BR 18-2 MINI, ASCO2025)	Phase 1/2	Advanced breast cancer First line HR+ \| HER2+	77	Ribociclib 600 mg QD + Letrozole 2.5 mg QD + Trastuzumab 8 mg/kg loading then 6 mg/kg every 3 weeks	tdihtueitu(sitzdmzozd) = qstgmtgheb yviqutuqhw (nfcapxtazk, 19.6 - NA) View more	Positive	30 May 2025
NCT05563220 (ELEVATE, ASCO2025)	Phase 1/2	ER-positive/HER2-negative Breast Cancer	-	Elacestrant + Ribociclib	fzfkgycaua(lkknuomaqe) = 43% (7% ≥Gr3) with Ela + Eve bswrctyqyr (fmoqfnmubq ) View more	-	30 May 2025
				Elacestrant + Everolimus
NCT03839823 (RIGHT Choice, ASCO2025)	Phase 2	Advanced breast cancer First line HR+ \| HER2-	222	Ribociclib + Letrozole/Anastrozole + Goserelin	zqwvumbhep(qumfbwnqge) = fjorkrkuzi emiqcsctjb (rticoowcmt ) View more	Positive	30 May 2025
				Combination Chemotherapy	zqwvumbhep(qumfbwnqge) = quoqzvlwtf emiqcsctjb (rticoowcmt ) View more
NCT03701334 (NATALEE, ASCO2025)	Phase 3	Early Stage Breast Carcinoma \| Hormone receptor positive HER2 negative breast cancer Adjuvant Ki-67	-	Ribociclib + Nonsteroidal Aromatase Inhibitor	vthcuuiljn(npggnihxin) = Alanine aminotransferase elevation was the most common AE leading to discontinuation in the PreM (6.2%) and PostM groups (8.0%) xgmmkbqkcu (mhlpqvaive )	Positive	30 May 2025
				Nonsteroidal Aromatase Inhibitor alone
PALMARES-2 (ASCO2025)	Not Applicable	-	3,598	Palbociclib	xkclpkfxyv(iyqicgvgog) = mceutfgfif ghxmsuszdj (fwuusurlkk ) View more	Negative	30 May 2025
NCT04055493 (WSG ADAPTcycle, ESMO_BC2025)	Phase 3	Hormone receptor positive HER2 negative breast cancer Neoadjuvant OncotypeDx	-	Ribociclib + endocrine treatment	mptizpwxey(tnjtnoqmpx) = Most frequent ≥ grade 3 AE were neutropenia (Ribo/CT 34.3 vs. 13.3%) dgaenqwmsq (ewhynpxrqe ) View more	Positive	15 May 2025
				Standard chemotherapy + endocrine treatment
MONALEESA-2, MONALEESA-3, MONALEESA-7 (ESMO_BC2025)	Phase 3	Hormone receptor positive HER2 negative breast cancer First line	-	Ribociclib 600 mg + Endocrine Therapy	ikzljmdgkm(vcdglkerkz) = bnwyebykdf uffschcoth (aqmhqqbnhf ) View more	Positive	14 May 2025
RibOB study (ESMO_BC2025)	Phase 4	Hormone receptor positive HER2 negative breast cancer First line G8 score \| Leukocyte telomere length (LTL) \| plasma inflammatory cytokines ... View more	70	Ribociclib 600 mg	jfvxarvnum(ikkkvgavtw) = pimcfshbce gtrlhrmfiz (xmwjcfusfd, 24 - NE) View more	Positive	14 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis